Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

DYAI - Dyadic International, Inc. So'nggi... | Finranks

Home

/

DYAI

D

Dyadic International, Inc. (DYAI)

NCM – Real vaqt narxi. Valyuta: USD

0.91

-0.14 (-13.17%)

Bozor ochiq: Aug 12, 2026, 12:36 PM EDT

1.05

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas

Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas

JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for the second quarter ended June 30, 2026, highlighting significant progress in product commercialization, strategic partnerships, and C1 biomanufacturing platform expansion.

Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

JUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food & nutrition, bioindustrial and biopharmaceutical markets, today announced the expansion of its commercial non-animal dairy pipeline through a new development and commercial license agreement with a European biotechnology company for additional precision-fermented dairy proteins.

Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026

Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026

JUPITER, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the quarter ended Jun 30, 2026 and host a corporate update conference call on Wednesday, August 12, 2026.

Videolar

No Data

There is no data to display

Press-relizlar

Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas

Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas

JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for the second quarter ended June 30, 2026, highlighting significant progress in product commercialization, strategic partnerships, and C1 biomanufacturing platform expansion.

Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

JUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food & nutrition, bioindustrial and biopharmaceutical markets, today announced the expansion of its commercial non-animal dairy pipeline through a new development and commercial license agreement with a European biotechnology company for additional precision-fermented dairy proteins.